TABLE 1.

Pharmacokinetic parameters of BMK-Y101 after ibulocydine administration

Parametersa	Intravenous (10 mg/kg)	Per Oral (10 mg/kg)	Intraperitoneal (5 mg/kg)
Cmax (μg/ml)	4.3 ± 0.51	0.36 ± 0.223	0.51 ± 0.208
tmax (h)	0.05 ± 0.029	1.1 ± 0.80	0.14 ± 0.048
tλ1/2 (h)	1.3 ± 0.31	2.0 ± 0.74	1.0 ± 0.05
AUC0–8h (μg h/ml)	1.76 ± 0.29	0.59 ± 0.064	0.51 ± 0.169
AUC0-∞ (μg h/ml)	1.77 ± 0.29	0.62 ± 0.074	0.51 ± 0.171
CL (liter/kg/h)
Vss (liter/kg)
MRT (h)	0.8 ± 0.04	2.2 ± 0.51	1.1 ± 0.10
Ae in urine8h (% of dose)	2.8 ± 0.73	0.67 ± 0.205	1.9 ± 0.787
A in Gl8h (% of dose)	4.9 ± 6.2	1.1 ± 0.62	4.5 ± 1.57
F (%)		33.9	57.7

^a C_max, maximum plasma concentration; t_max, time for C_max; t_λ1/2, terminal half-life; AUC_0–8h, area under the plasma concentration-time curve up to 8 hours; AUC_0–∞, area under the plasma concentration-time curve from time 0 to infinity; CL, total clearance from plasma; V_ss, steady-state volume of distribution; MRT, mean residence time; Ae in urine_8h, total amount of drug excreted in urine from time 0 to 8 h; A in Gl_8h, total amount of drug recovered from entire gastrointestinal tract from time 0 to 8 h; F, bioavailability (the ratio of AUC values between per oral and intravenous).